CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.33B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.12: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.91BCNY1.33B · vs all stocks (USD)
Trailing P/E
72.76xvs Biotechnology peers
Revenue (TTM)
1.40BCNY208.76M · vs all stocks (USD)
Profit Margin
8.38%vs Biotechnology peers
Beta
-0.1580xvs all stocks
52-Week Change
-21.25%vs all stocks
Market Capitalization
8.91BCNY1.33B · vs all stocks (USD)
Enterprise Value
6.59BCNY983.59M · vs all stocks (USD)
Trailing P/E
72.76xvs Biotechnology peers
Forward P/E
41.34xvs Biotechnology peers
Price to Sales (TTM)
6.09xvs Biotechnology peers
Price to Book (MRQ)
2.22xvs Biotechnology peers
Enterprise to Revenue
4.71xvs Biotechnology peers
Enterprise to EBITDA
28.16xvs Biotechnology peers
Gross Margin
72.24%vs Biotechnology peers
Profit Margin
8.38%vs Biotechnology peers
Operating Margin
11.85%vs Biotechnology peers
Return on Assets (TTM)
1.87%vs Biotechnology peers
Return on Equity (TTM)
2.95%vs Biotechnology peers
Revenue (TTM)
1.40BCNY208.76M · vs all stocks (USD)
Revenue per Share (TTM)
2.99CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-6.40%vs Biotechnology peers
Gross Profit (TTM)
972.16MCNY145.17M · vs all stocks (USD)
EBITDA (TTM)
360.79MCNY53.88M · vs all stocks (USD)
Net Income (TTM)
117.11MCNY17.49M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.80%vs Biotechnology peers
Operating Cash Flow (TTM)
323.20MCNY48.26M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
217.37MCNY32.46M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
48.24MCNYFY2025 · Dec 31, 2025Revenue
1.45BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
438.80MCNYFY2025 · Dec 31, 2025Gross Profit
1.02BCNYFY2025 · Dec 31, 2025Operating Income
196.55MCNY29.35M · vs all stocks (USD)
Pre-tax Income
174.45MCNYFY2025 · Dec 31, 2025Income Tax Expense
70.92MCNYFY2025 · Dec 31, 2025Net Income
103.53MCNYFY2025 · Dec 31, 2025EBIT
196.55MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
360.79MCNYFY2025 · Dec 31, 2025Research & Development
149.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
369.38MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.90MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
455.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
455.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
103.53MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.30MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
137.75MCNYFY2025 · Dec 31, 2025Free Cash Flow
88.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.01BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
103.53MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.69MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.20MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
32.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.25MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.18BCNYFY2025 · Dec 31, 2025Sale of Investments
2.48BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-747.85MCNYFY2025 · Dec 31, 2025Other Financing Charges
-68.86MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-68.86MCNYFY2025 · Dec 31, 2025Shares Outstanding
467.95MSharesUpdated Sep 21, 2026Float Shares
344.05MSharesUpdated Sep 21, 2026% Held by Insiders
29.75%vs all stocks
% Held by Institutions
5.89%vs all stocks
Total Cash (MRQ)
1.82BCNY271.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.99CNYUpdated Sep 21, 2026Total Debt (MRQ)
68.68MCNY10.26M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0182xvs Biotechnology peers
Current Ratio (MRQ)
1.91xvs Biotechnology peers
Book Value per Share (MRQ)
8.20CNYUpdated Sep 21, 2026Total Assets
5.29BCNY790.29M · vs all stocks (USD)
Total Current Assets
2.66BCNYFY2025 · Dec 31, 2025Total Liabilities
1.54BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.64BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
79.51MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.46BCNYFY2025 · Dec 31, 2025Cash
1.01BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.95MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.01BCNYFY2025 · Dec 31, 2025Other Short-term Investments
712.05MCNYFY2025 · Dec 31, 2025Accounts Receivable
605.87MCNYFY2025 · Dec 31, 2025Inventory
230.23MCNYFY2025 · Dec 31, 2025Accounts Payable
97.45MCNYFY2025 · Dec 31, 2025Short-term Debt
21.39MCNYFY2025 · Dec 31, 2025Other Current Liabilities
59.52MCNYFY2025 · Dec 31, 2025Long-term Debt
47.28MCNYFY2025 · Dec 31, 2025Common Stock (Book)
467.95MCNYFY2025 · Dec 31, 2025Retained Earnings
-103.25MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.75BCNY560.71M · vs all stocks (USD)
Treasury Stock
200.03MCNYFY2025 · Dec 31, 202552-Week Low
16.24CNYUpdated Sep 21, 202652-Week High
32.99CNYUpdated Sep 21, 202652-Week Change
-21.25%vs all stocks
Beta
-0.1580xvs all stocks
50-Day MA
19.08CNYUpdated Sep 21, 2026200-Day MA
23.59CNYUpdated Sep 21, 2026Avg 10-Day Volume
5.54MSharesUpdated Sep 21, 2026Avg 30-Day Volume
13.28MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.2500CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.12: safe zoneNotable
Altman Z-Score: 4.12
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.33B, above the global median of $1.18BNotable
Market cap (USD): 1,331,191,217.556Global Median: 1,180,223,658.953
Levered free cash flow is $32.46M, above the global median of $18.73MNotable
Levered free cash flow (USD): 32,459,986.343Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Electrical Apparatus Science Academy Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity